Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study.
Sánchez-Díaz M, Flórez Á, Ara-Martín M, Arias-Santiago S, Botella-Estrada R, Cañueto J, Carretero-Hernández G, Coto-Segura P, de Eusebio-Murillo E, García-Latasa de Araníbar FJ, García-Patos Briones V, Gardeazabal García J, Gómez-Fernández C, Hernández-Ostiz S, Izu Belloso R, López-Ávila A, Manchado López P, Martín-Santiago A, Martinez de Espronceda Ezquerro I, Mateu-Puchades A, Mercader-García P, Notario Rosa J, Palacio Aller L, Pérez-Hortet C, Quintana-Castanedo L, Rivera R, Rocamora Duran V, Rodríguez-Nevado IM, Ruiz-Villaverde R, Suárez J, Trasobares-Marugán L, Vizán-de Uña C, Yanguas I, Zulaica-Garate A, García-Doval I, Descalzo MÁ, Grau-Pérez M, Carrascosa-Carrillo JM.
Sánchez-Díaz M, et al.
Actas Dermosifiliogr. 2024 Mar;115(3):237-245. doi: 10.1016/j.ad.2023.10.016. Epub 2023 Oct 26.
Actas Dermosifiliogr. 2024.
PMID: 37890617
Free article.
English, Spanish.
The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across the autonomous communities. MATERIAL AND METHODS: Cross-sectional study conducted in April and May, 2023. Two dermatologists with ma …
The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across …